Interestingly, genetic or pharmacological ablation of ERBB2 and EGFR function, using EGFR small‐molecule irreversible inhibitor BIBW‐2992, diminishes the survival, anchorage‐independent growth, migration and invasion characteristics of gallbladder cancer cell lines, suggesting members of the EGFR family as an effective therapeutic target. Here, ERBB2 is linked to gallbladder cancer.